Hypoglycaemic peptides and methods of use thereof
CA 2452069 A1 · Owner: International Diabetes Institute · Inventors: Ng, Frank Man-Woon; Zimmet, Paul Zev
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A peptide of the formula (Xaa)n1-Xaa1-His-Thr-Asp-(Xaa)n2 wherein Xaa is any , amino acid; Xaa1 is a hydrophobic amino acid preferably Gly or Val; n1 is 0-, 10; and n2 is 0-10; and use thereof in regulating in vivo blood glucose levels in a human or other mammal, particularly in the treatment of Type 2 diabetes in a human. Preferably, the peptide is a tetrapeptide selected from Gly-His- Thr-Asp and Val-His-Thr-Asp. These hypoglycaemic peptides are isolated from human urine and they also have been chemically synthesized.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 27, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 27, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 27, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.